SCHEMBL6829248

SCHEMBL6829248

CC(=O)c1ccc(Nc2ncc(Br)c(Nc3ccc(F)cc3)n2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.64
CHEK1 O14757 2/20 0.61
NTRK2 Q16620 1/20 0.61
CDK1 P06493 2/20 0.56
PTK2 Q05397 1/20 0.56
AURKA O14965 6/20 0.55
IGF1R P08069 2/20 0.55
EGFR P00533 2/20 0.52
HDAC3 O15379 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
GSK3A P49840 1/20 0.51
CDK2 P24941 1/20 0.51
KDR P35968 1/20 0.51
FLT3 P36888 1/20 0.49
MAPK8 P45983 1/20 0.49
JAK2 O60674 1/20 0.49
AURKB Q96GD4 1/20 0.49
SYK P43405 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5262926 0.89 GSK3B (0.81) GSK3BCHEK1NTRK2CDK1PTK2
SCHEMBL6826344 0.85 GSK3B (0.55) GSK3BCHEK1NTRK2CDK1PTK2
SCHEMBL6826345 0.85 GSK3B (0.55) GSK3BCHEK1NTRK2CDK1PTK2
SCHEMBL6826392 0.83 AURKA (0.67) GSK3BCDK1AURKAIGF1RCDK2
SCHEMBL13648519 0.80 CDK1 (0.57) GSK3BCHEK1NTRK2CDK1CDK2
SCHEMBL4025895 0.80 CDK1 (0.70) GSK3BCHEK1NTRK2CDK1AURKA
SCHEMBL5262378 0.78 GSK3B (1.00) GSK3BCHEK1NTRK2CDK1AURKA
SCHEMBL13648524 0.78 TNK2 (0.53) GSK3BCHEK1NTRK2CDK1AURKA
SCHEMBL13648525 0.77 CDK1 (0.57) GSK3BCHEK1NTRK2CDK1CDK2
SCHEMBL13648652 0.77 CDK1 (0.57) GSK3BCHEK1NTRK2CDK1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004046118-A2 2-4-(DI-PHENYL-AMINO)-PYRIMIDINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2004-06-03 WO disclosed